MRNA Stock Forecast: Moderna Inc dips on concerns of allergic reactions to its COVID-19 vaccine

NASDAQ:MRNA falls 3.58% despite a market rally coming out of the MLK holiday.
The state of California halts the issuance of Moderna’s vaccine candidate because of allergic reactions.
Moderna’s CEO likens the COVID-19 vaccine market to the seasonal flu.

Stocks Reporter FXStreet

NASDAQ:MRNA has carried its momentum from the end of 2020 into 2021 so far as the stock has steadily risen throughout the first two trading weeks of the new year. On Tuesday, following the MLK extended holiday in the United States, Moderna shed 3.58% amidst a global market rally that saw the NASDAQ add 1.53% and the S&P 500 add 30 basis points. Moderna continues to be a global leader in the ongoing fight against the novel coronavirus, and investors have reaped the rewards as the stock is up nearly 520% over the past 52-weeks.

The pullback in price may be related to a recent report out of California that health officials had ordered a halt to the issuance of Moderna’s vaccine candidate mRNA-1273 due to allergic reactions from patients. This is not the first time that the issue of allergies has arisen, as Moderna’s rival Pfizer (NYSE:PFE) also reported reactions when its vaccine was issued in the United Kingdom. Apparently, over 300,000 vaccine doses have been put on pause until health officials can find out more about the reactions, which came from one specific clinic. The shipment that was delivered to that clinic, however, was a part of a larger shipment that distributed over 1.2 million doses around the United States.

MRNA stock price news

Recently, Moderna CEO Stephane Bancel caught the ear of investors when he stated that the COVID-19 vaccine could be a recurring seasonal dosage. While this isn’t great news for the population as a whole, it seems Moderna is expecting a recurring revenue stream from mRNA-1273 moving forward. Moderna is already expecting an estimated $11 billion in 2021 from mRNA-1273 alone.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Stocks Reporter

FXStreet

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

Editor's Picks

EUR/USD drops to daily lows near 1.1630

EUR/USD now loses some traction and slips back to the area of daily lows around 1.1630 on the back of a mild bounce in the US Dollar. Fresh US data, including the September PCE inflation numbers and the latest read on December consumer sentiment, didn’t really move the needle, so the pair is still on course to finish the week with a respectable gain.

GBP/USD trims gains, recedes toward 1.3320

GBP/USD is struggling to keep its daily advance, coming under fresh pressure and retreating to the 1.3320 zone following a mild bullish attempt in the Greenback. Even though US consumer sentiment surprised to the upside, the US Dollar isn’t getting much love, as traders are far more interested in what the Fed will say next week.

Gold makes a U-turn, back to $4,200

Gold is now losing the grip and receding to the key $4,200 region per troy ounce following some signs of life in the Greenback and a marked bounce in US Treasury yields across the board. The positive outlook for the precious metal, however, remains underpinned by steady bets for extra easing by the Fed.